BDD Pharma

February 19, 2020February 19, 2020

Oral Brilacidin Found to be Well-tolerated in Healthy Volunteers With Delivery Localized to the Colon, Trial Shows

News

Delayed-release oral tablets of brilacidin for ulcerative colitis (UC) was found delivered and dispersed into the colon, and was well-tolerated in healthy volunteers in a Phase 1 trial, announced the ... Read more

January 6, 2020January 7, 2020

UK Regulatory Agency Approves Launch of Innovation’s Phase 1 Trial of Brilacidin for Ulcerative Colitis

News

The United Kingdom’s Medicines and Healthcare products Regulatory Agency has approved the launch of Innovation Pharmaceuticals’ Phase 1 trial in healthy volunteers to investigate the safety and properties of delayed-release ... Read more

September 20, 2019September 20, 2019

Innovation Pharma Planning 1st Clinical Trial of Oral Brilacidin as Potential Ulcerative Colitis Treatment

News

Innovation Pharmaceuticals is planning a first clinical trial of an oral formulation of Brilacidin as a treatment for ulcerative colitis (UC), one of the most common types of inflammatory bowel disease (IBD). Brilacidin ... Read more

June 19, 2019June 19, 2019

Innovation Pharmaceuticals Signs Deal to Use Tablet Technology for Oral Brilacidin Treatment

News

Innovation Pharmaceuticals has signed an agreement to use OralogiK — an advanced tablet-coating technology patented by BDD Pharma — to develop tablets for targeted oral delivery of Brilacidin for treating ... Read more